Elanco has announced that Onsior 6 mg tablets have been licensed for the treatment of pain and inflammation associated with chronic musculoskeletal disorders in cats.

The NSAID's new indication is in addition to its existing license for acute pain and inflammation.

Elanco points to research it carried out which found that over a six week period, owners saw a visible improvement in their cats' performance of daily activities. There was also a 50% reduction in owner-assessed pain and disability (significantly greater than seen in the placebo group)1. 

The company says the product, which is administered once-daily as a small flavoured tablet, is well-accepted by most cats, and has a robust safety profile2. It is also a winner of an ISFM Easy to Give Award.

Elanco's Veterinary Technical Consultant, Lepha McCartan said: "It is very exciting to be launching this new indication for Onsior because musculoskeletal disorders are commonplace in cats.

"Although reports vary, studies have shown that radiographic evidence of DJD has a prevalence as high as over 90%.3

"At Elanco we are passionate about keeping cats doing what they love and Onsior enables this while also giving vets more choice for managing chronic musculo-skeletal disease."

For more information, visit: myelanco.co.uk or speak to your Elanco territory manager.

References

  1. Elanco Animal Health. Data on File: Lascelles BDX, King JN & Archer Thompson NJ (2018) ELA_ONS_Fel_CMSD_PFSS01
  2. EPAR – Assessment Report – Variation Elanco Animal Health.
  3. Lascelles BDX et al (2010) Cross sectional Study of the prevalence of radiographic DJD in domesticated cats. Vet Surg 2010 39: 535

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.